OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops biologically validated drivers of cancers medicines in the United States. The company's lead product candidate is the OKI-219, a selective inhibitor of PI3Ka harboring the H1047R mutation for the treatment of solid tumors, including breast cancer that is in Phase 1 clinical trial. OnKure Therapeutics, Inc. is headquartered in Boulder, Colorado.